|
题目
|
主讲人
|
|
Molecular Targeting in Microneoplasia, Where Prevention Meets Therapy
微小肿瘤的分子靶向：预防接近治疗？
|
获奖者: Scott Michael Lippman, MD
|
|
|
|
|
题目
|
主讲人
|
|
The evolution of umbilical cord blood in transplant medicine
脐血在移植医学中的发展
|
John Wagner, MD
|
|
Unrelated Donor Grafts for the Therapy of Hematological Malignancies
血液恶性肿瘤治疗中的非亲属供者移植
|
Claudio Anasetti, MD
|
|
题目
|
主讲人
|
|
Neoadjuvant vs. Adjuvant Therapy
新辅助治疗和辅助治疗的比较
|
Bruce J. Roth, MD
|
|
Surgical Aspects
外科治疗
|
Richard Hautmann, MD
|
|
The Molecular Biology of Bladder Carcinoma - Clinical Impact
膀胱癌的分子生物学：临床的影响
|
Guido Sauter, MD
|
|
Towards Curing Without Harming - Long-term Studies of Bladder Carcinoma Survivors
向无损害性治愈迈进：膀胱癌生存者的长期研究
|
Gunnar Steineck, PhD
|
|
题目
|
获奖者
|
|
From The Bedside to the Bench & Translational Research in Geriatric Oncology
老年肿瘤学：从临床到基础和转换性研究
|
Lodovico Balducci, MD
|
|
|
|
|
题目
|
主讲人
|
|
Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM): The Key to Neoplasia
意义不明的单克隆丙种球蛋白病(MGUS)和压抑性多发性骨髓瘤(SMM)：肿瘤的关键
|
获奖者: Robert A Kyle, MD
|
|
|
|
|
题目
|
主讲人
|
|
A global action: The UICC role
全球性活动：国际抗癌联盟(UICC)的作用
|
Franco Cavalli, MD
|
|
Chemoprevention in Breast Cancer
乳腺癌的化学预防
|
Bernard Fisher, MD
|
|
Lung Cancer and Smoking Prevention
肺癌和吸烟的预防
|
Richard Peto, FRS
|
|
Prevention in Colon Cancer
结肠癌的预防
|
Peter Greenwald, MD
|
|
The Use of Vaccines in Cervical and Hepatic Cancers
疫苗应用于宫颈癌及肝癌
|
Hakan Mellstedt, MD, PhD
|
|
题目
|
主讲人
|
|
Science of Oncology Award and Lecture and Special Awards
肿瘤科学奖、特殊贡献奖颁奖及演讲
|
获奖者: Evelyn H. Lauder
|
|
VEGF: From Basic Science To Human Therapy
VEGF：从基础到对人的治疗
|
获奖者: Napoleone Ferrara, MD
|
|
|
|
|
题目
|
主讲人
|
|
Anti-leukemia activity of histone deacetylase (HDAC) inhibitor LBH589 involves depletion of EZH2 and DNA methyltransferase (DNMT) 1 through disruption of their chaperone association with heat shock protein (hsp) 90.
组蛋白脱酰酶 (HDAC) 抑制剂LBH589的抗白血病活性涉及破坏hsp90相关伴侣蛋白、消耗EZH2和DNMT 1
摘要：No. 10501
|
Kapil N Bhalla, MD
|
|
Inhibition of poly (ADP-ribose) polymerase (PARP) by ABT-888 in patients with advanced malignancies: Results of a phase 0 trial.
进展期恶性肿瘤中ABT-888对聚ADP-核糖聚合酶(PARP) 的抑制：0期临床试验的结果
摘要：No. 3518
|
Shivaani Kummar, MD
|
|
Phase I and biomarker study of ABT869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies.
RTKs抑制剂ABT869治疗难治性实体恶性肿瘤的生物标记和I期研究
摘要：No. 3519
|
Chiung I Wong, MD
|
|
Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers.
Src激酶强口服抑制剂－AZD0530的I期研究：抑制人类肿瘤Src活性的第一个例证
摘要：No. 3520
|
Josep Tabernero, MD
|
|
Discussion
讨论
|
Edward Sausville, MD, PhD
|
|
题目
|
主讲人
|
|
Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31.
曲妥珠单抗(Trastuzumab)辅助治疗的益处不仅仅限于IHC 3+ 和/或 FISH-阳性的肿瘤患者：NSABP B-31中心试验结果
摘要：No. 511
|
Soonmyung Paik, MD
|
|
Prediction of response to bortezomib and dexamethasone resistance in myeloma (MM) by novel mutations in the NFKB pathway.
通过NFKB通路的新突变预测骨髓瘤对Bortezomib和DXM的耐药
摘要：No. 8007
|
Wee J Chng, MD
|
|
Validation of proteomic classifier for clinical benefit from erlotinib as first line treatment for advanced non-small cell lung cancer (ECOG 3503).
对erlotinib一线治疗进展期非小细胞肺癌的临床受益蛋白质组分类的评价(ECOG 3503)
摘要：No. 7508
|
Benjamin J Solomon, MBBS, FRACP
|
|
VEGF and VEGF receptor-2 (VEGFR2) gene polymorphisms predict tumor recurrence in stage II and III colon cancer.
VEGF/VEGFR-2 基因多态性预测II、III期结肠癌的复发
摘要：No. 4004
|
Georg Lurje, MD
|
|
Discussion
讨论
|
|
|
时间
|
题目
|
主讲人
|
|
3:40 PM - 3:50 PM
|
When the goal is not cure: A randomized trial of a patient decision aid in advanced colorectal cancer.
当目标不是治愈时，进展期结直肠癌患者决定辅助系统的随机试验
摘要：No. 6509
|
Natasha B Leighl, MD
|
|
3:50 PM - 4:00 PM
|
Discussion
讨论
|
Charles L Loprinzi, MD
|
|
4:05 PM - 4:15 PM
|
Incorporating a FLT3 inhibitor into AML therapy.
联合FLT3抑制剂治疗急性髓性白血病
摘要：No. 7060
|
Mark J Levis, MD, PhD
|
|
4:15 PM - 4:25 PM
|
Discussion
讨论
|
Gary Gilliland, MD, PhD
|
|
4:30 PM - 4:40 PM
|
Identification of genomic DNA signatures predicting relapse in low- and intermediate-risk neuroblastoma using a case control design and high-density SNP genotyping: A Children's Oncology Group (COG) study.
通过病例对照和高密度SNP基因型滴定预测中、低风险的神经细胞瘤肿瘤复发的基因组DNA印迹：儿童肿瘤研究组(COG)研究
摘要：No. 9500
|
Edward F Attiyeh, MD
|
|
4:40 PM - 4:50 PM
|
Discussion
讨论
|
Lee J. Helman, MD
|
|
4:55 PM - 5:05 PM
|
EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT).
HER2(+)乳腺癌脑转移患者在基于trastuzumab 全身化疗+颅脑放射后应用lapatinib治疗的II期研究
摘要：No. 1012
|
Nancy U Lin, MD
|
|
5:05 PM - 5:15 PM
|
Discussion
讨论
|
Mark D Pegram, MD
|
|
题目
|
主讲人
|
|
Report of the TRWG
TRWG报告
|
Ernest Hawk, MD, MPH
|
|
Translational development of interventions
医学干预的转换性研究进展
|
William G. Nelson, MD, PhD
|
|
Translational development of image-based risk assessment tools
基于影像的风险评估方法的转换性研究进展
|
Gary Dorfman, MD
|
